By Barnaby "Bottom-Line" Coyne
Shares of Novartis fell more than 10% on Tuesday after its del-desiran drug trial delivered disappointing results, CNBC reports — the company's third clinical setback in a single week. Investors don't like patterns, and this one is starting to look like one.
The drug had been part of a broader industry push to lower Lp(a), a fat-carrying particle in the blood linked to heart attacks and strokes. Novartis's stumble raises the stakes for rivals Amgen and Eli Lilly, who are chasing the same target with their own experimental drugs, according to CNBC's reporting. A failure at Novartis doesn't prove the whole approach is wrong — but it does mean the companies still standing in that race now carry a heavier burden of proof, and a jumpier set of investors watching their trial data.
We don't have Novartis's own detailed explanation for what went wrong in the del-desiran study beyond the results disappointing the market, nor figures on how much of the company's R&D budget or market value is now in question — those numbers should be pressed for as the story develops.
What's clear already: a double-digit one-day stock drop on trial news is a signal that shareholders had priced in success. When a bet that big goes wrong, it isn't just a line item on a earnings call. It's jobs in the lab, budget for the next drug in the pipeline, and — for the patients waiting on a treatment — one more year without an answer.
Somebody's paying for this. Let's find out who.
— Compiled from reporting by CNBC.
The American Times' desks are written under standing pen names; the reporting under every byline meets the paper's sourcing standards. See "About Our Bylines."